The minds behind Tempo.
Tempo Therapeutics is a privately held, clinical-stage regenerative medicine company in San Diego, developing synthetic biomaterials designed to enable the body to regenerate healthy tissue.

Eric Richman, MBA
Chief Executive Officer
Eric I. Richman is a biopharmaceutical executive, director, entrepreneur and investor with deep experience across biotechnology, pharmaceuticals, medical technology and healthcare services. He previously served as CEO of PharmAthene, LabConnect and Tyrogenex, and earlier spent 12 years at MedImmune from its inception, in commercial and strategic leadership roles. He began his career in venture capital at HealthCare Ventures and has also been affiliated with BroadOak Capital and Brace Pharma Capital. Mr. Richman has served on numerous public and private company boards, including Gain Therapeutics, ADMA Biologics, F2G, SafeHeal, MicroHealth Digital and others, and has extensive experience in corporate governance, capital formation, commercialization and strategic transactions. He also serves on the Scientific Advisory Board of Harvard Bioscience. He received a Bachelor of Biomedical Science from CUNY Medical School and an MBA from the Thunderbird School of Global Management at Arizona State University.

Westbrook Weaver, PhD
Founder & Chief Technology Officer
Westbrook is a co-inventor of Tempo’s MAP™ technology, and is the driving force behind early development at the company. He leads strategic and business development, as well as defining the critical path and leading company fundraising.

Donald Griffin, PhD
Founder & Chief Scientific Officer
Don is a co-inventor of MAP™ technology and a leading expert in biomaterial tissue engineering. He has over 14 years of experience as a researcher and Bioengineering professor and leads scientific & new technology efforts at Tempo.

Stephanie Deshayes, PhD
Vice President of Research & Development
Stephanie is an expert in organic chemistry, biomaterials, and drug delivery systems, with over 12 years of experience in the field. She leads Tempo’s on-the-ground efforts in developing the MAP™ platform and new technology breadth.

Philip Scumpia, MD, PhD
Vice President of Medical Affairs, Dermatology
Dr. Scumpia, a co-inventor of Tempo’s MAP™ technology, is a diplomate of the American Board of Dermatology and a member of the American Society of Dermatopathology and Society of Investigative Dermatology, and a Ph.D. immunologist. He currently practices clinical dermatology and dermatopathology at both UCLA health System and the West Los Angeles Veterans Affairs. Dr. Scumpia also runs an NIH-funded research program as a clinical professor in the David Geffen School of Medicine at UCLA. Dr. Scumpia has received numerous grants from the American Skin Cancer Association, the Dermatology Foundation, and the NIH. He has published 50 peer-reviewed manuscripts, including manuscripts in the prestigious journals Nature Materials and Nature Cell Biology.

Steven Sands
Chairman
Steven Sands’ professional experience began as a member of the Fixed Income Team with L.F. Rothschild. Thereafter, Steven leveraged his experience servicing both high net worth and institutional accounts at Oppenheimer & Co. He continued to broaden his experience at Laidlaw, Adams & Peck, where he focused on private equity and corporate finance. Eventually, Steven joined his brother, Martin, in the opening of Rodman & Renshaw’s New York office where his experience earned him a seat on the firm’s board. In 1990, they founded Sands Brothers and Co., a NYSE member investment bank and brokerage firm.
As the firm expanded, it included seats on the Toronto Stock Exchange, Montreal Bourse, and a passport license with the FSA (UK). This led to the opening of its technology-based San Francisco office and the creation of Sands Brother Asset Management, which funded investments in a broad spectrum of industries.
As Co-CEO of Sands Brothers Asset Management, Steven managed the Select Access Funds, Sands Brothers Venture Capital funds, as well as numerous other special purpose vehicles. In addition, he has worked closely with his brother Martin in assembling, acquiring, and selling over 500,000 square feet of commercial office space.
In 2007, Steven cofounded Genesis Merchant Partners (“GMP”) to offer strategic and opportunistic asset-based and secured loans in underserved markets. GMP offered financing to companies with strong assets and cash flows in niche markets that were often overlooked by banks and other traditional providers of capital.
Steven earned a bachelor’s degree from Hamilton College. He has been a director of numerous public and private companies across a wide range of industries including Bright Point Inc., a wireless technology company later acquired by Ingram Micro, and Air Methods, a medical air transport company that was acquired by American Securities. He has served as a trustee of the Friends School in Locust Valley, New York, chairs a foundation dedicated to better human outcomes with his children and is active in numerous other charitable endeavors. He lives in Locust Valley, New York with his wife.

Eric Richman, MBA
Director

Westbrook Weaver, PhD
Director

Donald Griffin, PhD
Director

Biren Mehta
Director
Based in Irvine, California, Biren Mehta is the Vice President, Venture Investments – MedTech, where he initiates and manages equity investments to drive business innovation and deliver new and sustainable business for the MedTech sector. He is responsible for JJDC MedTech in the Western half of the US. Previously, Biren was Vice President of Business Development for the Cardiovascular & Specialty Solutions (CSS) Group and J&J Vision. This represents a portfolio of six diverse, high-growth businesses within MedTech.
Prior to joining Johnson & Johnson, Biren was a medical device analyst at Roth Capital Partners, where he focused on the MedTech sector. He began his career with software engineer stints at Computer Motion and IntraLase. Biren completed his bachelor’s degree in Cybernetics at UCLA. He earned master’s degrees in Biomedical Engineering and Computer Science from the University of Southern California. He also earned his MBA from the UCLA Anderson School of Management.

Erik Oros
Director
Erik Oros is the Chief Investment Officer at Gideon Strategic Partners, where he leads the firm’s investment strategy with a holistic, macro-driven approach to asset management. He oversees Gideon’s managed registered portfolios and its proprietary private markets access platform. In this role, Erik also serves in an active leadership capacity with the firm’s portfolio companies, serving on the boards of OTTO Aviation, RADAR, FusionIQ, Safeheal, Tsavorite Scalable Intelligence, General Proximity, and Osteal Therapeutics.
Prior to joining Gideon, Erik was the Founder and CIO of Actinium Capital LP, a global long/short equity hedge fund investing across sectors and geographies. He began his career on the buy-side at Salient Partners, where he was a member of the global equity team with primary responsibility for the technology, media, and telecom sectors. Before Salient, he completed a comprehensive analyst rotation program at UBS in New York.
Erik holds a B.A. in Mathematics and Economics from the University of Pennsylvania and an M.S. in Applied Economics from Johns Hopkins University with a concentration in financial economics. He is a Chartered Financial Analyst (CFA) and a Chartered Alternative Investment Analyst (CAIA).

Dino Di Carlo, PhD
Founder, Scientific Advisor
Dino Di Carlo is the Armond and Elena Hairapetian Professor and Chair of Bioengineering at UCLA, a serial entrepreneur, and inventor. He is a co-inventor of the MAP™ technology and co-founder of Tempo Therapeutics, serving on the board of directors from 2014-2024. He is an author of >190 peer-reviewed articles and an inventor of >70 issued patents in the U.S. and across the world. In addition to his academic roles, he has a history of business leadership roles. He co-founded companies in the diagnostics, medical device, and biotech/pharmaceutical industries and continues to serve on the board of directors of many of these companies, and as a scientific advisor and mentor to startups. He has received numerous awards, including the Presidential Early Career Award for Scientists and Engineers (PECASE), the highest honor bestowed upon young scientists and engineers in the U.S.

Babak Azizzadeh, MD, FACS
Clinical Advisor
Dr. Babak Azizzadeh is an internationally recognized facial plastic and reconstructive surgeon specializing in advanced facial rejuvenation, deep plane facelift surgery, and facial reanimation with reconstruction. He is the President-Elect of the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS), Associate Clinical Professor of Surgery at UCLA and an attending surgeon with multiple leadership positions at Cedars-Sinai Health Systems for over two decades. Dr. Azizzadeh has authored numerous peer-reviewed scientific publications and surgical textbook chapters and is a recognized pioneer in advancing techniques for facial rejuvenation and reconstruction. His clinical and research interests include facial aging, facial nerve disorders, wound healing, and regenerative medicine. As co-founder of MACRO Trials, he has also been involved in advancing FDA-regulated clinical research and emerging medical technologies. His expertise bridges aesthetic and reconstructive surgery with the clinical development of next-generation treatments.

Tatiana Segura, PhD
Founder, Scientific Advisor
Dr. Segura is a professor of Biomedical Engineering, Neurology and Dermatology at Duke University and is a co-inventor of Tempo’s MAP™ technology. Professor Segura’s laboratory studies the use of materials for minimally invasive in situ tissue repair. On this topic, she has published over 60 peer-reviewed publications. She has been recognized with the Outstanding Young Investigator Award from the American Society of Gene and Cell Therapy, the American Heart Association National Scientist Development Grant, and the CAREER award from National Science Foundation. She was elected to the College of Fellows at the American Institute for Medical and Biological Engineers (AIMBE) in 2017.
Steve Yoelin, MD
Clinical Advisor
Bio coming soonBuilt with partners in industry and academia.
Organizations Tempo has worked with across research, development and financing.
- $14.5MSeptember 2026
- $12MMarch 2024
- ~$2.25MNIH / National Cancer Institute SBIR award, 2026
- ~$5.5MAdditional NIH & NSF grant funding received since 2017
- MedTech Innovator2025 Accelerator Cohort
- Join usAt Tempo, we’re always looking for talented individuals to help us grow and make a difference. There are no open roles right now. View careers and future opportunities →